Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Antimetastatic activity of a cyclooxygenase-2 inhibitor.

Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH.

Br J Cancer. 2004 Jul 19;91(2):359-65.

2.

Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.

Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, Bouchier-Hayes DJ.

Br J Cancer. 2002 Jul 15;87(2):231-7.

4.

Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.

Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC.

J Urol. 2000 Sep;164(3 Pt 1):820-5.

PMID:
10953162
5.

Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.

Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G.

Clin Cancer Res. 2003 Oct 1;9(12):4324-31.

6.

Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.

Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L.

Cancer Res. 2000 Mar 1;60(5):1326-31.

7.

Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.

Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ.

Cancer Biol Ther. 2004 Dec;3(12):1217-24. Epub 2004 Dec 9.

PMID:
15477758
8.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

10.

NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.

Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM.

J Am Coll Surg. 2004 Sep;199(3):428-35.

PMID:
15325613
11.

Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.

Kundu N, Walser TC, Ma X, Fulton AM.

Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13.

PMID:
15891886
12.
14.

Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.

Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M.

Lab Invest. 1999 Dec;79(12):1469-77.

PMID:
10616198
15.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

16.

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.

Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, Sunami E, Nita ME, Ishihara S, Yano H, Tsuruo T, Shibata Y, Muto T.

Br J Cancer. 1999 Dec;81(8):1274-9.

17.

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.

Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K.

Br J Cancer. 2007 Dec 3;97(11):1523-31. Epub 2007 Oct 30.

18.

The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.

Fenwick SW, Toogood GJ, Lodge JP, Hull MA.

Gastroenterology. 2003 Sep;125(3):716-29.

PMID:
12949718
19.
20.
Items per page

Supplemental Content

Write to the Help Desk